Compare Amgen, Inc. (AMGN) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Trump Media and Technology Group Corp — how do they compare? Amgen, Inc. trades at $363.26 (market cap $196.12B), while Trump Media and Technology Group Corp trades at $8.56 (market cap $2.37B). The key difference: Amgen, Inc. is far larger — about 82.8× Trump Media and Technology Group Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| AMGN | DJT | |
|---|---|---|
Market Cap | $196.12B | $2.37B |
Sector | Health | Media |
52-Week High | $388.16 | $19.86 |
52-Week Low | $271.18 | $7.06 |
Enterprise Value | $241.41B | $2.32B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DJT trades at $8.54, down 0.12% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported 2025 revenue of $3.68M but a net loss of -$712.06M, with a negative net income margin of -29,098.97%. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of plans to spin off Truth Social, while the merger with TAE Technologies remains pending.
The outlook is highly speculative with severe financial losses and minimal revenue growth, posing significant risks. Investment potential hinges on the TAE merger and Truth Social's expansion, but high volatility and negative profitability warrant extreme caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
